Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study

医学 哮喘 呼出气一氧化氮 安慰剂 嗜酸性粒细胞 内科学 过敏 置信区间 恶化 随机对照试验 奥马佐单抗 空气过敏原 欧洲联盟 免疫学 支气管收缩 免疫球蛋白E 过敏原 病理 替代医学 抗体 业务 经济政策
作者
Jonathan Corren,Christopher S. Ambrose,Janet M. Griffiths,Åsa Hellqvist,Andrew Lindsley,Jean‐Pierre Llanos,Gene Colice,Andrew Menzies‐Gow
出处
期刊:Clinical & Experimental Allergy [Wiley]
卷期号:53 (4): 417-428 被引量:18
标识
DOI:10.1111/cea.14256
摘要

Abstract Background Allergic asthma is the most common phenotype among patients with severe asthma. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab significantly reduced the annualized asthma exacerbation rate (AAER) versus placebo in patients with severe, uncontrolled asthma. This exploratory analysis evaluated the efficacy of tezepelumab in NAVIGATOR participants with evidence of severe allergic asthma. Methods Patients (12–80 years old) receiving medium‐ or high‐dose inhaled corticosteroids and ≥ 1 additional controller medication, with or without oral corticosteroids, were randomized to tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks in NAVIGATOR. In this analysis, the AAER, forced expiratory volume in 1 second (FEV 1 ), patient‐reported outcomes (PROs), and type 2 biomarker levels were evaluated in patients grouped by sensitivity to perennial aeroallergens, confirmed symptomatic allergy, and eligibility for omalizumab treatment according to the United States (OMA‐US) and the European Union (OMA‐EU) prescribing information, including subgroups according to baseline blood eosinophil counts and fractional exhaled nitric oxide (FeNO) levels. Results Of 1059 patients who received treatment in NAVIGATOR, 680 (64%) had perennial aeroallergen sensitivity and 318 (30%) had confirmed symptomatic allergy; 379 (36%) and 359 (34%) patients were OMA‐US‐ and OMA‐EU‐eligible, respectively. Tezepelumab reduced the AAER over 52 weeks versus placebo by 58% (95% confidence interval [CI]: 47–67) to 68% (95% CI: 55–77) across these subgroups. Among omalizumab‐eligible patients, AAERs were reduced in patients across baseline blood eosinophil counts and FeNO levels. Tezepelumab improved FEV 1 and PROs, and reduced type 2 biomarkers, versus placebo in patients with and without perennial allergy. Conclusions Tezepelumab was efficacious in patients with severe, uncontrolled asthma with evidence of allergic inflammation, defined by multiple clinically relevant definitions. These findings further support the benefits of tezepelumab in a broad population of patients with severe asthma, including those with severe allergic asthma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
狂野元枫完成签到 ,获得积分10
刚刚
ruochenzu发布了新的文献求助10
3秒前
大葱鸭发布了新的文献求助10
3秒前
ABC完成签到,获得积分20
5秒前
原本发布了新的文献求助10
5秒前
dzy完成签到,获得积分20
6秒前
amber完成签到 ,获得积分10
6秒前
Green完成签到,获得积分10
8秒前
9秒前
小木子完成签到,获得积分10
11秒前
舟遥遥完成签到,获得积分10
12秒前
华仔应助大橙子采纳,获得10
14秒前
桐桐应助Bismarck采纳,获得10
18秒前
CLY完成签到,获得积分10
19秒前
20秒前
rita_sun1969完成签到,获得积分10
21秒前
研友_8K2QJZ完成签到,获得积分10
21秒前
蝴蝶完成签到 ,获得积分10
22秒前
ARIA完成签到 ,获得积分10
22秒前
大橙子发布了新的文献求助10
25秒前
Bismarck完成签到,获得积分20
26秒前
26秒前
爱笑子默完成签到,获得积分10
27秒前
27秒前
一点完成签到,获得积分10
29秒前
研友_VZG7GZ应助大葱鸭采纳,获得10
29秒前
DezhaoWang完成签到,获得积分10
30秒前
知犯何逆发布了新的文献求助10
31秒前
原本完成签到,获得积分10
31秒前
Bismarck发布了新的文献求助10
32秒前
苗条丹南完成签到 ,获得积分10
34秒前
yu完成签到 ,获得积分10
37秒前
skyleon完成签到,获得积分10
37秒前
无心的天真完成签到 ,获得积分10
38秒前
Engen完成签到,获得积分20
38秒前
39秒前
学术小垃圾完成签到,获得积分10
39秒前
dreamwalk完成签到 ,获得积分10
39秒前
黄淮科研小白龙完成签到 ,获得积分10
40秒前
齐嫒琳完成签到,获得积分10
42秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022